Scott R. Struthers's most recent trade in Crinetics Pharmaceuticals Inc was a trade of 313,000 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on Sept. 1, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Crinetics Pharma Inc | R. Scott Struthers | Director, President & CEO | Sale or transfer of securities back to the company at price $ 0.00 per share. | 01 Sep 2026 | 313,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Crinetics Pharma Inc | R. Scott Struthers | Director, President & CEO | Sale or transfer of securities back to the company at price $ 0.00 per share. | 01 Sep 2026 | 287,700 | 0 | - | - | Stock Option (Right to Buy) | |
| Crinetics Pharma Inc | R. Scott Struthers | Director, President & CEO | Sale or transfer of securities back to the company at price $ 0.00 per share. | 01 Sep 2026 | 259,058 | 0 | - | - | Stock Option (Right to Buy) | |
| Crinetics Pharma Inc | R. Scott Struthers | Director, President & CEO | Sale or transfer of securities back to the company at price $ 85.00 per share. | 01 Sep 2026 | 248,043 | 176,663 (0%) | 1% | 85 | 21,083,655 | Common Stock |
| Crinetics Pharma Inc | R. Scott Struthers | Director, President & CEO | Sale or transfer of securities back to the company at price $ 0.00 per share. | 01 Sep 2026 | 244,205 | 0 | - | - | Stock Option (Right to Buy) | |
| Crinetics Pharma Inc | R. Scott Struthers | Director, President & CEO | Sale or transfer of securities back to the company at price $ 0.00 per share. | 01 Sep 2026 | 240,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Crinetics Pharma Inc | R. Scott Struthers | Director, President & CEO | Sale or transfer of securities back to the company at price $ 0.00 per share. | 01 Sep 2026 | 228,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Crinetics Pharma Inc | R. Scott Struthers | Director, President & CEO | Sale or transfer of securities back to the company at price $ 0.00 per share. | 01 Sep 2026 | 195,578 | 0 | - | - | Stock Option (Right to Buy) | |
| Crinetics Pharma Inc | R. Scott Struthers | Director, President & CEO | Sale or transfer of securities back to the company at price $ 85.00 per share. | 01 Sep 2026 | 176,663 | 0 (0%) | 0% | 85 | 15,016,355 | Common Stock |
| Crinetics Pharma Inc | R. Scott Struthers | Director, President & CEO | Sale or transfer of securities back to the company at price $ 0.00 per share. | 01 Sep 2026 | 172,281 | 0 | - | - | Stock Option (Right to Buy) | |
| Crinetics Pharma Inc | R. Scott Struthers | Director, President & CEO | Sale or transfer of securities back to the company at price $ 85.00 per share. | 01 Sep 2026 | 136,805 | 0 (0%) | 0% | 85 | 11,628,425 | Common Stock |
| Crinetics Pharma Inc | R. Scott Struthers | Director, President & CEO | Sale or transfer of securities back to the company at price $ 85.00 per share. | 01 Sep 2026 | 111,100 | 0 (0%) | 0% | 85 | 9,443,500 | Common Stock |
| Crinetics Pharma Inc | R. Scott Struthers | Director, President & CEO | Sale or transfer of securities back to the company at price $ 85.00 per share. | 01 Sep 2026 | 111,100 | 0 (0%) | 0% | 85 | 9,443,500 | Common Stock |
| Crinetics Pharma Inc | R. Scott Struthers | Director, President & CEO | Sale or transfer of securities back to the company at price $ 85.00 per share. | 01 Sep 2026 | 111,100 | 0 (0%) | 0% | 85 | 9,443,500 | Common Stock |
| Crinetics Pharma Inc | R. Scott Struthers | Director, President & CEO | Sale or transfer of securities back to the company at price $ 85.00 per share. | 01 Sep 2026 | 111,100 | 0 (0%) | 0% | 85 | 9,443,500 | Common Stock |
| Crinetics Pharma Inc | R. Scott Struthers | Director, President & CEO | Sale or transfer of securities back to the company at price $ 85.00 per share. | 01 Sep 2026 | 110,000 | 0 (0%) | 0% | 85 | 9,350,000 | Common Stock |
| Crinetics Pharma Inc | R. Scott Struthers | Director, President & CEO | Sale or transfer of securities back to the company at price $ 85.00 per share. | 01 Sep 2026 | 106,000 | 0 (0%) | 0% | 85 | 9,010,000 | Common Stock |
| Crinetics Pharma Inc | R. Scott Struthers | Director, President & CEO | Sale or transfer of securities back to the company at price $ 85.00 per share. | 01 Sep 2026 | 100,000 | 0 (0%) | 0% | 85 | 8,500,000 | Common Stock |
| Crinetics Pharma Inc | R. Scott Struthers | Director, President & CEO | Sale or transfer of securities back to the company at price $ 85.00 per share. | 01 Sep 2026 | 80,000 | 0 (0%) | 0% | 85 | 6,800,000 | Common Stock |
| Crinetics Pharma Inc | R. Scott Struthers | Director, President & CEO | Sale or transfer of securities back to the company at price $ 85.00 per share. | 01 Sep 2026 | 1,000 | 0 (0%) | 0% | 85 | 85,000 | Common Stock |
| Crinetics Pharma Inc | R. Scott Struthers | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Aug 2026 | 6,542 | 259,058 | - | - | Stock Option (Right to Buy) | |
| Crinetics Pharma Inc | R. Scott Struthers | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 15.29 per share. | 07 Aug 2026 | 6,542 | 419,711 (1%) | 0% | 15.3 | 100,027 | Common Stock |
| Crinetics Pharma Inc | R. Scott Struthers | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Aug 2026 | 4,995 | 244,205 | - | - | Stock Option (Right to Buy) | |
| Crinetics Pharma Inc | R. Scott Struthers | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 20.02 per share. | 07 Aug 2026 | 4,995 | 424,706 (1%) | 0% | 20.0 | 100,000 | Common Stock |
| Crinetics Pharma Inc | R. Scott Struthers | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Aug 2026 | 4,422 | 195,578 | - | - | Stock Option (Right to Buy) | |
| Crinetics Pharma Inc | R. Scott Struthers | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 22.61 per share. | 07 Aug 2026 | 4,422 | 413,169 (1%) | 0% | 22.6 | 99,981 | Common Stock |
| Crinetics Pharma Inc | R. Scott Struthers | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 25.19 per share. | 07 Aug 2026 | 3,969 | 408,747 (1%) | 0% | 25.2 | 99,979 | Common Stock |
| Crinetics Pharma Inc | R. Scott Struthers | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Aug 2026 | 3,969 | 172,281 | - | - | Stock Option (Right to Buy) | |
| Crinetics Pharma Inc | R. Scott Struthers | Director, President & CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 29 May 2026 | 222,200 | 223,200 (0%) | 0% | 0 | Common Stock | |
| Crinetics Pharma Inc | R. Scott Struthers | Director, President & CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 29 May 2026 | 222,200 | 626,978 (2%) | 0% | 0 | Common Stock | |
| Crinetics Pharma Inc | R. Scott Struthers | Director, President & CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 29 May 2026 | 222,200 | 216,805 (0%) | 0% | 0 | Common Stock | |
| Crinetics Pharma Inc | R. Scott Struthers | Director, President & CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 29 May 2026 | 222,200 | 439,005 (1%) | 0% | 0 | Common Stock | |
| Crinetics Pharma Inc | R. Scott Struthers | Director, President & CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 29 May 2026 | 111,100 | 111,100 (0%) | 0% | 0 | Common Stock | |
| Crinetics Pharma Inc | R. Scott Struthers | Director, President & CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 29 May 2026 | 111,100 | 111,100 (0%) | 0% | 0 | Common Stock | |
| Crinetics Pharma Inc | R. Scott Struthers | Director, President & CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 29 May 2026 | 111,100 | 1,000 (0%) | 0% | 0 | Common Stock | |
| Crinetics Pharma Inc | R. Scott Struthers | Director, President & CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 29 May 2026 | 111,100 | 112,100 (0%) | 0% | 0 | Common Stock | |
| Crinetics Pharma Inc | R. Scott Struthers | Director, President & CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 29 May 2026 | 111,100 | 111,100 (0%) | 0% | 0 | Common Stock | |
| Crinetics Pharma Inc | R. Scott Struthers | Director, President & CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 29 May 2026 | 111,100 | 111,100 (0%) | 0% | 0 | Common Stock | |
| Crinetics Pharma Inc | R. Scott Struthers | Director, President & CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 29 May 2026 | 111,100 | 404,778 (1%) | 0% | 0 | Common Stock | |
| Crinetics Pharma Inc | R. Scott Struthers | Director, President & CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 29 May 2026 | 111,100 | 515,878 (2%) | 0% | 0 | Common Stock | |
| Crinetics Pharma Inc | R. Scott Struthers | Director, President & CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 29 May 2026 | 80,000 | 136,805 (0%) | 0% | 0 | Common Stock | |
| Crinetics Pharma Inc | R. Scott Struthers | Director, President & CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 29 May 2026 | 80,000 | 80,000 (0%) | 0% | 0 | Common Stock | |
| Crinetics Pharma Inc | R. Scott Struthers | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 37.11 per share. | 16 Mar 2026 | 13,196 | 413,563 (1%) | 0% | 37.1 | 489,704 | Common Stock |
| Crinetics Pharma Inc | R. Scott Struthers | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 37.77 per share. | 16 Mar 2026 | 8,785 | 404,778 (1%) | 0% | 37.8 | 331,809 | Common Stock |
| Crinetics Pharma Inc | R. Scott Struthers | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Dec 2025 | 28,400 | 259,058 | - | - | Stock Option (Right to Buy) | |
| Crinetics Pharma Inc | R. Scott Struthers | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 15.29 per share. | 18 Dec 2025 | 28,400 | 364,759 (1%) | 0% | 15.3 | 434,236 | Common Stock |
| Crinetics Pharma Inc | R. Scott Struthers | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 9.28 per share. | 18 Dec 2025 | 16,342 | 336,359 (1%) | 0% | 9.3 | 151,654 | Common Stock |
| Crinetics Pharma Inc | R. Scott Struthers | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Dec 2025 | 16,342 | 0 | - | - | Stock Option (Right to Buy) | |
| Crinetics Pharma Inc | R. Scott Struthers | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 45.00 per share. | 26 Sep 2025 | 4,000 | 106,000 (0%) | 0% | 45 | 180,000 | Common Stock |
| Crinetics Pharma Inc | R. Scott Struthers | Director, President & CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 14 May 2025 | 90,400 | 320,017 (1%) | 0% | 0 | Common Stock | |
| Crinetics Pharma Inc | R. Scott Struthers | Director, President & CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 14 May 2025 | 90,400 | 661,205 (2%) | 0% | 0 | Common Stock | |
| Crinetics Pharma Inc | R. Scott Struthers | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.91 per share. | 02 Apr 2025 | 81,270 | 410,417 (1%) | 0% | 1.9 | 155,226 | Common Stock |
| Crinetics Pharma Inc | R. Scott Struthers | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Apr 2025 | 81,270 | 0 | - | - | Stock Option (Right to Buy) | |
| Crinetics Pharma Inc | R. Scott Struthers | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 34.17 per share. | 19 Mar 2025 | 16,463 | 330,022 (1%) | 0% | 34.2 | 562,541 | Common Stock |
| Crinetics Pharma Inc | R. Scott Struthers | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 34.83 per share. | 19 Mar 2025 | 875 | 329,147 (1%) | 0% | 34.8 | 30,476 | Common Stock |
| Crinetics Pharma Inc | R. Scott Struthers | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Feb 2025 | 313,000 | 313,000 | - | - | Stock Option (Right to Buy) | |
| Crinetics Pharma Inc | R. Scott Struthers | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Feb 2025 | 89,000 | 346,485 (1%) | 0% | 0 | Common Stock | |
| Crinetics Pharma Inc | Struthers R. Scott | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 57.57 per share. | 02 Dec 2024 | 10,000 | 100,000 (0%) | 0% | 57.6 | 575,700 | Common Stock |
| Crinetics Pharma Inc | R. Scott Struthers | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 9.28 per share. | 08 May 2024 | 107,448 | 364,933 (1%) | 0% | 9.3 | 997,117 | Common Stock |
| Crinetics Pharma Inc | R. Scott Struthers | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 May 2024 | 107,448 | 16,342 | - | - | Stock Option (Right to Buy) | |
| Crinetics Pharma Inc | R. Scott Struthers | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 49.40 per share. | 08 May 2024 | 107,448 | 257,485 (1%) | 0% | 49.4 | 5,307,931 | Common Stock |
| Crinetics Pharma Inc | R. Scott Struthers | Director, President & CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 18 Apr 2024 | 350 | 257,485 (1%) | 0% | 0 | Common Stock | |
| Crinetics Pharma Inc | R. Scott Struthers | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.91 per share. | 15 Apr 2024 | 20,000 | 257,835 (1%) | 0% | 1.9 | 38,200 | Common Stock |
| Crinetics Pharma Inc | R. Scott Struthers | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Apr 2024 | 20,000 | 81,270 | - | - | Stock Option (Right to Buy) | |
| Crinetics Pharma Inc | R. Scott Struthers | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 9.28 per share. | 04 Apr 2024 | 40,951 | 278,786 (1%) | 0% | 9.3 | 380,025 | Common Stock |
| Crinetics Pharma Inc | R. Scott Struthers | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Apr 2024 | 40,951 | 123,790 | - | - | Non-qualified stock option (Right to Buy) | |
| Crinetics Pharma Inc | R. Scott Struthers | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 49.17 per share. | 04 Apr 2024 | 40,951 | 237,835 (0%) | 0% | 49.2 | 2,013,561 | Common Stock |
| Crinetics Pharma Inc | R. Scott Struthers | Director, President & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 38.14 per share. | 18 Mar 2024 | 12,687 | 237,835 (0%) | 0% | 38.1 | 483,882 | Common Stock |
| Crinetics Pharma Inc | R. Scott Struthers | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2024 | 240,000 | 240,000 | - | - | Stock Option (right to buy) | |
| Crinetics Pharma Inc | R. Scott Struthers | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2024 | 65,000 | 250,522 (1%) | 0% | 0 | Common Stock | |
| Crinetics Pharma Inc | Scott Struthers R. | Director, President & CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 12 Feb 2024 | 60,000 | 570,805 (2%) | 0% | 0 | Common Stock | |
| Crinetics Pharma Inc | Scott R. Struthers | Director, President & CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 12 Feb 2024 | 20,000 | 110,000 (0%) | 0% | 0 | Common Stock | |
| Crinetics Pharma Inc | R. Struthers Scott | Director, President & CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 12 Feb 2024 | 20,000 | 110,000 (0%) | 0% | 0 | Common Stock | |
| Crinetics Pharma Inc | Struthers Scott R. | Director, President & CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 12 Feb 2024 | 20,000 | 110,000 (0%) | 0% | 0 | Common Stock | |
| Crinetics Pharma Inc | R. Scott Struthers | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Aug 2023 | 10,000 | 151,270 | - | - | Incentve stock option (Right to Buy) | |
| Crinetics Pharma Inc | R. Scott Struthers | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.91 per share. | 14 Aug 2023 | 10,000 | 135,522 (0%) | 0% | 1.9 | 19,100 | Common Stock |
| Crinetics Pharma Inc | R. Scott Struthers | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 20.14 per share. | 11 Jul 2023 | 24,384 | 656,421 (2%) | 0% | 20.1 | 491,094 | Common Stock |
| Crinetics Pharma Inc | R. Scott Struthers | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 20.35 per share. | 11 Jul 2023 | 14,157 | 630,805 (2%) | 0% | 20.4 | 288,095 | Common Stock |
| Crinetics Pharma Inc | R. Scott Struthers | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 20.17 per share. | 11 Jul 2023 | 11,459 | 644,962 (2%) | 0% | 20.2 | 231,128 | Common Stock |
| Crinetics Pharma Inc | R. Scott Struthers | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 20.81 per share. | 16 Jun 2023 | 50,000 | 680,805 (2%) | 0% | 20.8 | 1,040,500 | Common Stock |
| Crinetics Pharma Inc | R. Scott Struthers | Director, President & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 17.12 per share. | 16 Mar 2023 | 4,628 | 125,522 (0%) | 0% | 17.1 | 79,231 | Common Stock |
| Crinetics Pharma Inc | R. Scott Struthers | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2023 | 287,700 | 287,700 | - | - | Common Stock (right to buy) | |
| Crinetics Pharma Inc | R. Scott Struthers | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2023 | 61,650 | 130,150 (0%) | 0% | 0 | Common Stock | |
| Crinetics Pharma Inc | R. Scott Struthers | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Oct 2022 | 11,100 | 161,270 | - | - | Incentive stock option (Right to Buy) | |
| Crinetics Pharma Inc | R. Scott Struthers | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.91 per share. | 12 Oct 2022 | 11,100 | 68,500 (0%) | 0% | 1.9 | 21,201 | Common Stock |
| Crinetics Pharma Inc | R. Scott Struthers | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 27.53 per share. | 13 Apr 2022 | 69,176 | 730,805 (3%) | 0% | 27.5 | 1,904,256 | Common Stock |
| Crinetics Pharma Inc | R. Scott Struthers | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 26.52 per share. | 13 Apr 2022 | 44,793 | 799,981 (3%) | 0% | 26.5 | 1,188,040 | Common Stock |
| Crinetics Pharma Inc | R. Scott Struthers | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 25.42 per share. | 13 Apr 2022 | 24,674 | 844,774 (3%) | 0% | 25.4 | 627,329 | Common Stock |
| Crinetics Pharma Inc | R. Scott Struthers | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 25.34 per share. | 05 Apr 2022 | 21,357 | 869,448 (3%) | 0% | 25.3 | 541,225 | Common Stock |
| Crinetics Pharma Inc | R. Scott Struthers | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2022 | 249,200 | 249,200 | - | - | Common Stock (right to buy) | |
| Crinetics Pharma Inc | R. Scott Struthers | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2022 | 53,400 | 57,400 (0%) | 0% | 0 | Common Stock |